ABSTRACT The efficacy of intracoronary urokinase and streptokinase were compared in 80 patients with acute myocardial infarction in a prospective, randomized, double-blind study. Urokinase was infused into the occluded coronary artery at 6000 U/min, and streptokinase was infused at 2000 U/min. 
INTRACORONARY THROMBOLYSIS is being intensively investigated for use in treatment of patients with acute myocardial infarction. Streptokinase is the drug commonly used. However, urokinase, a potent thrombolytic enzyme, has theoretical advantages. Urokinase is an intrinsic body constituent and is not antigenic. Antibody-mediated resistance does not occur with urokinase. Urokinase directly activates plasminogen to plasmin, whereas streptokinase must form a complex with plasminogen before becoming activated. Urokinase and streptokinase have equal clinical efficacy in the thrombolytic therapy of patients with pulmonary emboli based on studies supported by the National Heart, Blood and Lung Institute.' This study was conducted to compare urokinase and streptokinase in the intracoronary thrombolytic therapy of patients with acute myocardial infarction. Received July 21, 1983; revision accepted Dec. 15, 1983. 756 Methods This was a randomized, double-blind, parallel study of the efficacy of intracoronary urokinase (Abbokinase; Abbott Pharmaceuticals) and streptokinase (Streptase; Hoechst-Roussel Pharmaceuticals, Inc.) in treating patients with acute myocardial infarction.
Patients were eligible for inclusion in the study under the following conditions: (1) typical symptoms of myocardial infarction occurred less than 12 hr before infusion, (2) electrocardiogram showed short-term changes of myocardial infarction, (3) no specific contraindication to thrombolytic therapy existed, and (4) angiographic demonstration of a completely occluded vessel related to the infarct. After informed consent was obtained, the hospital pharmacy randomized the patient to receive either urokinase or streptokinase. Unlabeled thrombolytic solution, containing either streptokinase at a concentration of 500 IU/ml or urokinase at a concentration of 1500 U/ml, was supplied by the pharmacy. All medical personnel and the clinical investigators outside the pharmacy were blinded as to the thrombolytic drug used. Baseline coagulation studies before catheterization included measurements of serum fibrinogen, fibrin split products, thrombin time, prothrombin time, partial thromboplastin time, and plasminogen levels. In the catheterization laboratory, left ventricular and coronary angiography were performed. Heparin was given without knowledge of the treatment group in bolus doses ranging from 2500 U to 10,000 U. The thrombolytic solution was then infused into the occluded infarct-related vessel at a rate of 4 ml/min (2000 U of streptokinase per minute or Antegrade flow of contrast past a site of previous occlusion was used to define opening. The occluded artery opened and remained open to the end of the study in 27 patients receiving urokinase and in 20 patients receiving streptokinase. The success rate for the drugs in the two treatment groups (60% for urokinase and 57% for streptokinase) was not different (p = .797). Urokinase was not effective in five of 18 patients in the urokinase group because their arteries had transient opening but reoccluded before the study concluded. Streptokinase was not effective in two of 15 patients in the streptokinase group because their arteries had a transient opening only.
Duration of therapy. There is a trend to earlier openings of arteries with urokinase. More patients in whom urokinase was not effective had therapy discontinued before the maximal 2 hr infusion than did patients in the streptokinase group; only one patient had urokinase therapy discontinued because of hemodynamic instability. Hence, total infusion times were longer for patients receiving streptokinase (table 4) .
Fibrinogen levels. Fibrinogen levels measured in 70 patients before infusion of drug averaged 294 mg/dl (±57) for the streptokinase group and 299 mg/dl ( 53) for the urokinase group. Fibrinogen levels after infusion of drug were determined in 63 patients (34 patients receiving urokinase and 29 receiving streptokinase). Decreases in fibrinogen levels occurred in most patients. However, of the 34 patients receiving urokinase, only two (6%) had fibrinogen, levels less than 100 mg/dl, while 19 of 29 (66%) patients receiving streptokinase had levels less than 100 mg/dl. These proportions are significantly different (p < .001). As with major bleeding had fibrinogen levels less than 100 mg/dl. Thirty-two of our patients underwent coronary artery bypass surgery. Ten of these patients had surgery less than 20 hr after infusion (a time interval when a thrombolytic-induced tendency to bleed might still be present).2 Four of the five patients undergoing early surgery who were given streptokinase had major hemorrhagic complications, whereas none of five given urokinase had major bleeding events. Three of four patients undergoing early surgery who had bleeding complications had fibrinogen levels less than 100 mg/ dl, whereas five of six nonbleeders had fibrinogen levels greater than 100 mg/dl.
Discussion
Phase II of the pulmonary embolism trial of the National Heart, Lung and Blood Institute demonstrated that urokinase and streptokinase have essentially equal efficacy in thrombolytic therapy for patients with pulmonary emboli.' Streptokinase is a foreign body seen in figure 1, protein with inherent problems of allergic reactions and antibody-mediated resistance. However, urokinase is not antigenic, but is costly to produce.
In the doses used in this study, urokinase and streptokinase are equally efficacious for patients with intracoronary thrombolysis. The percentage opening of occluded vessels and the speed of thrombolysis are similar with both drugs. The recanalization rate of approximately 60% is lower than that reported by many groups,3-' but similar to that of others.4 6.7 Our success rate has remained consistent throughout the course of our experience.
The efficacy of either drug may be dosage dependent. The pulmonary embolism trial of the National Heart, Lung and Blood Institute used a loading dose for both drugs. Urokinase was then infused at a rate of 2000 U/pound/hr intravenously, and streptokinase was infused at a rate of 100,000 U/hr for maintenance of intravenous infusion. For thrombolytic action may develop and prevent effective retreatment for 3 to 6 months.9 Since urokinase is an intrinsic body constituent, it should have no antigenicity and should be an effective retreatment for patients previously treated with either streptokinase or urokinase.
Streptokinase lowered systemic fibrinogen levels more than urokinase in our study. If systemic fibrinogen levels less than 100 mg/dl are accepted as a measure of systemic fibrinolysis, then the incidence of systemic fibrinolysis is also significantly greater with streptokinase than with urokinase. While initial reports of intracoronary thrombolysis suggested little systemic effect on the coagulation system,8 several reports confirm significant reduction in systemic fibrinogen levels after infusion of intracoronary streptokinase.10 11 It is possible that the rate and duration of infusion of streptokinase we used is excessive for intracoronary infusion, thereby leading to a systemic effect on fibrinogen levels. The total duration of the streptokinase infusion was longer than the urokinase infusion in our study, but duration of infusion seems to have little relationship to fall in fibrinogen levels for streptokinase ( figure  1 ). Patients treated with streptokinase in the pulmonary embolism trial of the National Heart, Lung and Blood Institute also had significantly lower levels of plasma fibrinogen than did the patients treated with urokinase. 12 Why does streptokinase have greater systemic fibrinolysis than urokinase? Streptokinase and urokinase appear to activate both plasma and thrombus plasminogen. Infusion of these drugs may result in saturation of a2-antiplasmin binding sites and cause a state of systemic hyperplasminemia. The resultant hyperplasminemia could cause fibrinogen degradation. Hypofibrinogenemia, products of fibrinogen lysis, and their interference with platelet aggregation, result in hemorrhagic diatheses. 13 The half-life of urokinase is shorter than that of streptokinase,14' 15 which perhaps explains the lessened systemic effect on most patients receiving urokinase. Other as yet unexplained mechanisms may be responsible for the observed differences in systemic fibrinolytic activity. Bioassay fibrinogen levels are generally depressed over 24 hr after infusion of streptokinase.2 More recent studies suggest that immunoassay fibrinogen levels are not suppressed. Streptokinase-induced bleeding diatheses and depressed bioassay fibrinogen levels may be caused by fibrinogen fragments possibly interacting with heparin.'6 Similar data regarding bioassay and immunoassay fibrinogen regeneration after intracoronary administration of urokinase are not available.
Previous studies have correlated bleeding complications of thrombolytic drugs with low fibrinogen levels and/or increased thrombin times."17 18 Bleeding is usually a multifactorial process involving vascular integrity, platelet action, and the coagulation system. While there is indication that major bleeding is more common with reduced fibrinogen levels, factors such as heparin anticoagulation, length of time before removal of arterial catheter, and the patient's ability to protect arterial puncture site are obvious additional variables. In this study, postoperative bleeding after recent thrombolytic therapy is clearly more common in the patients receiving streptokinase. Urokinase is a safer drug for patients in whom the possibility of early operative intervention is considered. There is clear indication that patients with fibrinogen levels less than 100 mg/dl have an increased risk of perioperative bleeding. We now give these patients clotting factors intraoperatively to try to normalize abnormal parameters.
In summary, urokinase and streptokinase in dosages used in this study are equally effective intracoronary thrombolytic drugs. Urokinase produces less systemic fibrinolysis. Patients receiving urokinase who are undergoing early surgery have less perioperative bleeding than a similar group of patients receiving streptokinase.
